These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 9510119)

  • 1. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs.
    Michelangeli V; Poon C; Taft J; Newnham H; Topliss D; Colman P
    Thyroid; 1998 Feb; 8(2):119-24. PubMed ID: 9510119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
    Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease.
    Shibayama K; Ohyama Y; Yokota Y; Ohtsu S; Takubo N; Matsuura N
    Endocr J; 2005 Oct; 52(5):505-10. PubMed ID: 16284425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K; Tamai H; Matsubayashi S; Mukuta T; Morita T; Kubo C; Kuma K
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term follow up after antithyroid drug treatment in Graves' disease].
    Wille T; Müller B; Noth D; Bürgi U; Diem P
    Praxis (Bern 1994); 2006 Jul; 95(29-30):1121-7. PubMed ID: 16916174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
    Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.
    Cho BY; Shong MH; Yi KH; Lee HK; Koh CS; Min HK
    Clin Endocrinol (Oxf); 1992 Jun; 36(6):585-90. PubMed ID: 1358483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
    Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
    Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of TSH-receptor antibodies as prognostic markers after cessation of antithyroid drug treatment in patients with Graves' disease.
    Kasagi K; Iida Y; Hatabu H; Tokuda Y; Arai K; Endo K; Konishi J
    Acta Endocrinol (Copenh); 1988 Feb; 117(2):173-80. PubMed ID: 2454576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two Graves' disease patients who spontaneously developed hypothyroidism after antithyroid drug treatment: characteristics of epitopes for thyrotropin receptor antibodies.
    Chung HK; Kim WB; Park DJ; Kohn LD; Tahara K; Cho BY
    Thyroid; 1999 Apr; 9(4):393-9. PubMed ID: 10319947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ; Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.